Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Eiger BioPharmaceuticals stock | $7.86

Learn how to easily invest in Eiger BioPharmaceuticals stock.

Eiger BioPharmaceuticals, Inc
NASDAQ: EIGR - USD
BIOTECHNOLOGY
$7.96
-$0.19 (-2.33%)

Eiger BioPharmaceuticals, Inc is a biotechnology business based in the US. Eiger BioPharmaceuticals shares (EIGR) are listed on the NASDAQ and all prices are listed in US Dollars. Eiger BioPharmaceuticals employs 31 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Eiger BioPharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EIGR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Eiger BioPharmaceuticals stock price (NASDAQ: EIGR)

Use our graph to track the performance of EIGR stocks over time.

Eiger BioPharmaceuticals shares at a glance

Information last updated 2021-07-28.
Latest market close$7.86
52-week range$7.57 - $13.49
50-day moving average $8.28
200-day moving average $9.15
Wall St. target price$32.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.65

Buy Eiger BioPharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Eiger BioPharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eiger BioPharmaceuticals price performance over time

Historical closes compared with the close of $7.86 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) -6.76%
3 months (2021-04-30) -7.42%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Eiger BioPharmaceuticals financials

Revenue TTM $3.6 million
Gross profit TTM $0
Return on assets TTM -29.95%
Return on equity TTM -24.28%
Profit margin 0%
Book value $3.72
Market capitalisation $280.4 million

TTM: trailing 12 months

Shorting Eiger BioPharmaceuticals shares

There are currently 879,636 Eiger BioPharmaceuticals shares held short by investors – that's known as Eiger BioPharmaceuticals's "short interest". This figure is 1.6% up from 865,498 last month.

There are a few different ways that this level of interest in shorting Eiger BioPharmaceuticals shares can be evaluated.

Eiger BioPharmaceuticals's "short interest ratio" (SIR)

Eiger BioPharmaceuticals's "short interest ratio" (SIR) is the quantity of Eiger BioPharmaceuticals shares currently shorted divided by the average quantity of Eiger BioPharmaceuticals shares traded daily (recently around 223257.8680203). Eiger BioPharmaceuticals's SIR currently stands at 3.94. In other words for every 100,000 Eiger BioPharmaceuticals shares traded daily on the market, roughly 3940 shares are currently held short.

However Eiger BioPharmaceuticals's short interest can also be evaluated against the total number of Eiger BioPharmaceuticals shares, or, against the total number of tradable Eiger BioPharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eiger BioPharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Eiger BioPharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0303% of the tradable shares (for every 100,000 tradable Eiger BioPharmaceuticals shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eiger BioPharmaceuticals.

Find out more about how you can short Eiger BioPharmaceuticals stock.

Eiger BioPharmaceuticals share dividends

We're not expecting Eiger BioPharmaceuticals to pay a dividend over the next 12 months.

Have Eiger BioPharmaceuticals's shares ever split?

Eiger BioPharmaceuticals's shares were split on a 1:15 basis on 22 March 2016. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eiger BioPharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Eiger BioPharmaceuticals shares which in turn could have impacted Eiger BioPharmaceuticals's share price.

Eiger BioPharmaceuticals share price volatility

Over the last 12 months, Eiger BioPharmaceuticals's shares have ranged in value from as little as $7.57 up to $13.49. A popular way to gauge a stock's volatility is its "beta".

EIGR.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eiger BioPharmaceuticals's is 1.3515. This would suggest that Eiger BioPharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Eiger BioPharmaceuticals overview

Eiger BioPharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California. .

Stocks similar to Eiger BioPharmaceuticals

Frequently asked questions

What percentage of Eiger BioPharmaceuticals is owned by insiders or institutions?
Currently 1.223% of Eiger BioPharmaceuticals shares are held by insiders and 69.37% by institutions.
How many people work for Eiger BioPharmaceuticals?
Latest data suggests 31 work at Eiger BioPharmaceuticals.
When does the fiscal year end for Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals's fiscal year ends in December.
Where is Eiger BioPharmaceuticals based?
Eiger BioPharmaceuticals's address is: 2155 Park Boulevard, Palo Alto, CA, United States, 94306
What is Eiger BioPharmaceuticals's ISIN number?
Eiger BioPharmaceuticals's international securities identification number is: US28249U1051
What is Eiger BioPharmaceuticals's CUSIP number?
Eiger BioPharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 15117E107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site